Skip to main navigation

For Investors
News
Careers
Contact Us
COVID-19 Candidate Updates

About Us
- Our Team
- Our Partners
Our Pipeline
Science and Technology
Resources

About Us
- Our Team
- Our Partners
Our Pipeline
Science and Technology
Resources
For Investors
News
Careers
Contact Us
COVID-19 Candidate Updates

Press Releases & Statements

Investor Relations

Month Year

Su	Mo	Tu	We	Th	Fr	Sa

Month Year

Su	Mo	Tu	We	Th	Fr	Sa

Year Category Keywords

Advanced Search

Search

Search Headlines Only

Category

From

To

Asset Types

Photos Video Audio Documents Events Standard

Novavax Reconfirms Confidence in Regulatory Filing Timelines and Manufacturing Quality
- Statement
- COVID-19
Oct 20, 2021
Novavax Statement on Initial Com-COV2 Phase 2 Clinical Trial Results Presented at World Vaccine Congress Europe
- Statement
- COVID-19
Oct 19, 2021
Novavax to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights on November 4, 2021
- Corporate and Finance
Oct 18, 2021
Novavax to Participate in World Vaccine Congress Europe
- COVID-19
- Seasonal Influenza
Oct 15, 2021
Complete PREVENT-19 Phase 3 Clinical Trial Results Manuscript for COVID-19 Vaccine Posted to medRxiv
- Statement
- COVID-19
Oct 11, 2021
Novavax Announces Leadership Appointment and Updates
- Corporate and Finance
Oct 4, 2021
Novavax to Participate in Health Equity and Vaccine Confidence Panel at Maryland Life Sciences Bio Innovation Conference
- COVID-19
Sep 29, 2021
Novavax Hosts HM King Carl XVI Gustaf and HM Queen Silvia of Sweden During Royal Visit to Uppsala County
- COVID-19
Sep 24, 2021
Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases
- Seasonal Influenza
Sep 23, 2021
Novavax and Serum Institute of India Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine
- COVID-19
Sep 23, 2021
Novavax to Participate in Fireside Chat at the 2021 Cantor Virtual Global Healthcare Conference
- Corporate and Finance
Sep 23, 2021
Novavax to Participate in Fireside Chat at Devex @ UNGA 76
- COVID-19
Sep 20, 2021
Novavax Statement on Proof of COVID-19 Vaccine Requirements for PREVENT-19 Clinical Trial Participants in the U.S.
- Statement
- COVID-19
Sep 17, 2021
Novavax to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 Vaccine Schedule in Adolescents
- COVID-19
Sep 16, 2021
Novavax Statement on Takeda Agreement to Provide 150 Million Doses of NVX-CoV2373 to the Government of Japan
- Statement
- COVID-19
Sep 10, 2021
Novavax to Participate in Upcoming September Conferences
- Corporate and Finance
Sep 9, 2021
Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
- COVID-19
Sep 8, 2021
Novavax to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
- Corporate and Finance
Sep 7, 2021
Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants
- COVID-19
Aug 30, 2021
Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems
- COVID-19
Aug 25, 2021
Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance
- Corporate and Finance
Aug 16, 2021
Novavax Reports Second Quarter 2021 Financial Results and Operational Highlights

Aug 5, 2021
Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination
- COVID-19
Aug 5, 2021
Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine
- COVID-19
Aug 5, 2021
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine
- COVID-19
Aug 4, 2021
Novavax to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights on August 5, 2021
- Corporate and Finance
Jul 6, 2021
Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine
- COVID-19
Jun 30, 2021
Novavax Statement on Proof of Vaccination for Phase 3 Clinical Trial Participants: Updated June 30, 2021
- Statement
- COVID-19
Jun 30, 2021
Novavax Statement on Completion of the National Research Council of Canada Biologics Manufacturing Centre
- Statement
- COVID-19
Jun 22, 2021
Novavax to Participate in Fireside Chat at SVB Leerink CybeRx Series: Vaccine Forum
- Corporate and Finance
Jun 17, 2021
Novavax to Participate in National Vaccine Advisory Committee Meeting
- Corporate and Finance
Jun 17, 2021
Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
- COVID-19
- Seasonal Influenza
Jun 14, 2021
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
- COVID-19
Jun 14, 2021
Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine
- COVID-19
Jun 11, 2021
Novavax to Host Maryland Governor Larry Hogan at Site of Future Novavax Vaccines Innovation Campus and Global Headquarters
- Corporate and Finance
Jun 9, 2021
Novavax to Participate in Panel at BIO Digital 2021
- COVID-19
Jun 7, 2021
Novavax to Participate in Jefferies Virtual Healthcare Conference
- COVID-19
May 27, 2021
Novavax to Present at International Society for Vaccines Virtual Congress COVID-19 Vaccine Update
- COVID-19
May 24, 2021
Novavax Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine Activities in South Korea
- COVID-19
May 22, 2021
Novavax Statement on Proof of Vaccination for Phase 3 Clinical Trial Participants in the United Kingdom
- Statement
- COVID-19
May 22, 2021
Complete Trial Results Manuscript of Novavax COVID-19 Investigational Vaccine Posted to Preprint Server medRxiv
- Statement
- COVID-19
May 21, 2021
Novavax Statement on Participation in Mix-and-Match COVID-19 Vaccine Booster Trial in the United Kingdom
- Statement
- COVID-19
May 21, 2021
Novavax Honored by Maryland Tech Council During 2021 Industry Awards Celebration
- Corporate and Finance
May 21, 2021
Novavax Reports First Quarter 2021 Financial Results and Operational Highlights
- Corporate and Finance
May 10, 2021
Novavax Statement on Updated PREVENT-19 Trial Protocol
- Statement
- COVID-19
May 10, 2021
Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
- COVID-19
- Seasonal Influenza
May 10, 2021
Novavax Statement on Ministry of Health, Labour and Welfare’s Announcement Regarding Procurement from Takeda of NVX-CoV2373 for Japan
- Statement
- COVID-19
May 7, 2021
Novavax Statement in Opposition to the WTO TRIPS Waiver
- Statement
- COVID-19
May 7, 2021
Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility
- COVID-19
May 6, 2021
New England Journal of Medicine Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant

May 5, 2021
Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine

May 3, 2021
Novavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021

Apr 23, 2021
Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet
- Matrix-M™ Adjuvant
Apr 23, 2021
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
- COVID-19
Apr 14, 2021
Novavax Announces Leadership Updates
- Corporate and Finance
Apr 13, 2021
Novavax to Participate in Fireside Chat at Goldman Sachs Virtual Conference
- Corporate and Finance
Apr 8, 2021
Novavax CEO Stan Erck to Participate in Longwood Healthcare Leaders Meeting
- Corporate and Finance
Apr 5, 2021
Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover
- COVID-19
Apr 5, 2021
GSK to support manufacture of Novavax' COVID-19 vaccine
- COVID-19
Mar 29, 2021
Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials
- COVID-19
Mar 11, 2021
Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat
- Corporate and Finance
Mar 8, 2021
Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
- Corporate and Finance
Mar 1, 2021
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
- COVID-19
Feb 26, 2021
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
- COVID-19
Feb 22, 2021
Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine
- COVID-19
Feb 18, 2021
Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results and Operational Highlights on March 1, 2021
- Corporate and Finance
Feb 16, 2021
Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea
- COVID-19
Feb 15, 2021
Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
- COVID-19
Feb 4, 2021
Novavax and Government of Switzerland Announce Agreement in Principle to Supply COVID-19 Vaccine
- COVID-19
Feb 3, 2021
Novavax Announces Memorandum of Understanding to Produce COVID-19 Vaccine Made in Canada
- COVID-19
Feb 2, 2021
Novavax to Present COVID-19 Vaccine Candidate Data at New York Academy of Science
- COVID-19
Feb 1, 2021
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
- COVID-19
Jan 28, 2021
Novavax Names Madelyn Caltabiano Senior Vice President, Global Program Management
- Corporate and Finance
Jan 22, 2021
Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine
- COVID-19
Jan 22, 2021
Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer
- Corporate and Finance
Jan 15, 2021
Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine
- COVID-19
Jan 7, 2021
Novavax to Participate in Upcoming Conferences
- Corporate and Finance
Jan 6, 2021
Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico
- COVID-19
Dec 28, 2020
Biopharma Executive Rick Crowley Joins Novavax as Chief Operations Officer
- Corporate and Finance
Dec 21, 2020
Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine
- COVID-19
Dec 16, 2020
Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors
- Corporate and Finance
Dec 9, 2020
Novavax Announces COVID-19 Vaccine Clinical Development Progress
- COVID-19
Nov 30, 2020
Novavax to Participate in Upcoming Conferences
- Corporate and Finance
Nov 25, 2020
Novavax to Host Conference Call for Questions Related to Third Quarter Financial and Operating Results on November 10, 2020
- Corporate and Finance
Nov 10, 2020
Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA
- COVID-19
Nov 9, 2020
Novavax Appoints Gregory F. Covino as Chief Financial Officer and Announces Leadership Updates
- Corporate and Finance
Nov 9, 2020
Novavax Reports Third Quarter 2020 Financial and Operational Results
- Corporate and Finance
Nov 9, 2020
Novavax and Commonwealth of Australia Announce Agreement in Principle for Acquisition of Novavax COVID-19 Vaccine
- COVID-19
Nov 4, 2020
Novavax to Host Conference Call to Discuss Third Quarter Financial and Operating Results on November 9, 2020
- Corporate and Finance
Nov 3, 2020
Novavax Appoints Biopharmaceutical Industry Veteran Gregg Alton to Board of Directors
- Corporate and Finance
Nov 3, 2020
Novavax Announces Facility Expansion to Support Global Vaccine Development
- COVID-19
Nov 2, 2020
Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
- COVID-19
Oct 27, 2020
Novavax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020
- COVID-19
Oct 20, 2020
Novavax Appoints Leadership Team to Advance NanoFlu through Regulatory Licensure
- Seasonal Influenza
Oct 13, 2020
Novavax to Participate in Upcoming Conferences
- Corporate and Finance
Oct 5, 2020
Novavax to Present COVID-19, Influenza and RSV Candidate Vaccine Data at World Vaccine Congress Washington 2020
- COVID-19
Sep 28, 2020
Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom
- COVID-19
Sep 24, 2020
Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2 Billion Doses Annually
- COVID-19
Sep 15, 2020
Novavax to Participate in Upcoming Investor Conferences
- Corporate and Finance
Sep 10, 2020
Biopharma Leaders Unite to Stand with Science
- Partners
Sep 8, 2020

Show 5 10 25 50 100 per page

«
1
2
3
»

Site - Shareholder Tools

Print Page
Email Alerts

For Investors
News

Contact Us
- 21 Firstfield Road
  Gaithersburg, MD 20878
  
  (240) 268-2000
Social
Site - Footer Social
- Privacy Policy | Terms and Conditions
  
  Pay Transparency Nondiscrimination Provision
  
  Purchase Order Terms and Conditions

This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. By clicking ‘Accept’ you are indicating your consent for us to place these cookies. For more information, please read our Privacy Policy or manage your cookie settings.

Accept